Advertisement

 

 

Subsequent Malignancies After Allogeneic Hematopoietic Stem Cell Transplantation.

Subsequent Malignancies After Allogeneic Hematopoietic Stem Cell Transplantation.
Author Information (click to view)

Gündüz M, Özen M, Şahin U, Toprak SK, Civriz Bozdağ S, Kurt Yüksel M, Arslan Ö, Özcan M, Demirer T, Beksaç M, İlhan O, Gürman G, Topçuoğlu P,


Gündüz M, Özen M, Şahin U, Toprak SK, Civriz Bozdağ S, Kurt Yüksel M, Arslan Ö, Özcan M, Demirer T, Beksaç M, İlhan O, Gürman G, Topçuoğlu P, (click to view)

Gündüz M, Özen M, Şahin U, Toprak SK, Civriz Bozdağ S, Kurt Yüksel M, Arslan Ö, Özcan M, Demirer T, Beksaç M, İlhan O, Gürman G, Topçuoğlu P,

Advertisement

Clinical transplantation 2017 04 22() doi 10.1111/ctr.12987
Abstract

We evaluated 979 patients for the development of post-transplant lymphoproliferative disease (PTLD) and solid malignancies after allogeneic hematopoietic stem cell transplantations (allo-HSCT) as a late complication. We found 15 (1.5%) subsequent malignancies; three of these malignancies were PTLD, and twelve were solid tumors. The median time from allo-HSCT to the development of PTLD was 9 (3-20) months and that from allo-HSCT to the development of solid tumors was 93 (6-316) months. The cumulative incidence of evolving subsequent malignancy in patients was 1.3% (±0.5 SE) at 5 years and 3.9% (±1.2 SE) at 10 years. The Cumulative incidence of developing subsequent malignancy in patients with benign hematological diseases as the transplant indication was 7.4%±4.2SE at 5 years. More subsequent malignancy developed in patients having ≥1 year chronic GVHD (3.7% in ≥1 year chronic GVHD and 0.7% in <1 year chronic GVHD patient groups, p=0.002). Subsequent epithelial tumor risk was higher in ≥1 year chronic GVHD patients than <1 year (3.7% vs 0.1%, p<0.001). In multivariate analysis, benign hematological diseases as transplant indication (RR:5.6, CI 95%: 1.4-22.3, p=0.015) and ≥1 year chronic GVHD (RR:7.1, CI95%: 2.3-22.5, p=0.001) were associated with the development of subsequent malignancy. This article is protected by copyright. All rights reserved.

Submit a Comment

Your email address will not be published. Required fields are marked *

2 × four =

[ HIDE/SHOW ]